Boston Scientific Corporation (BSX) has had a bumpy ride this year with its
stock price experiencing some ups and downs. Despite
lagging in the early part of the year, some analysts still consider the stock
expensive but worth it. The company reported
encouraging results for Q2 of 2025 and even though it was marginally
down since its last earnings report, experts believe there is potential for a rebound.
Boston Scientific, amidst other bio-tech companies, is one to keep an eye on. However, BSX recently made the decision to recall its
Wallstent Monorail system. Despite this setback, some analysts believe Boston Scientific still has room to grow compared to other healthcare stocks. Meanwhile,
Jefferies maintains a buy rating on the company, setting a price target of $130. In contrast, insiders at the company sold US$2.3m in stock, alluding to potential qualitative weakness. This notwithstanding,
BSX’s stock outperformed the healthcare sector and showed
growth of 117% on a key product. As various market forces continue to influence the company’s stock performance, investors continue to evaluate whether BSX remains a viable addition to their portfolio.
Boston Scientific Corp BSX News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Fri, 29 Aug 2025 13:40:02 GMT -
Rating 2
- Innovation 6
- Information 5
- Rumor -3
